A review on the role of Siglec-7 in ovarian cancer and related molecular docking studies

Abstract

Ovarian cancer is one of the most lethal gynecological cancers in the world. Recent developments in immunology have revealed that ovarian cancer uses Siglec-7 protein. It is a sialic acid-binding immunoglobulin-like lectin that is expressed on natural killer cells. The pathophysiology of ovarian cancer and the potential of Siglec-7 as a therapeutic target are explored in this review. The focus is particularly on α-2,8-disialic acid motifs. This review also focuses on molecular docking studies in the literature concerning Siglec-7. Analysis of C9-modified sialosides have revealed enhanced hydrophobic interaction upon modifications with biphenyl and oxamido derivatives. A collection of new tailor-constructed sialic acid analogues with combined C4 azido, C9 aromatic, and triazole modifications are reviewed. A combination of functional group changes was made based on previous studies that showed chemical modifications with favorable results. A thorough approach for docking, receptor-ligand preparation is also carried out in this review.